353 related articles for article (PubMed ID: 22988651)
21. [Cutaneous side effects of EGFR inhibitors--appearance and management].
Wollenberg A; Kroth J; Hauschild A; Dirschka T
Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
[TBL] [Abstract][Full Text] [Related]
22. Cutaneous side-effects of EGFR inhibitors and their management.
Ehmann LM; Ruzicka T; Wollenberg A
Skin Therapy Lett; 2011 Jan; 16(1):1-3. PubMed ID: 21293833
[TBL] [Abstract][Full Text] [Related]
23. Common side effects of anti-EGFR therapy: acneform rash.
Sipples R
Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):28-34. PubMed ID: 16616284
[TBL] [Abstract][Full Text] [Related]
24. [Acneiform eruptions induced by cetuximab].
Walon L; Gilbeau C; Lachapelle JM
Ann Dermatol Venereol; 2003 Apr; 130(4):443-6. PubMed ID: 12843857
[TBL] [Abstract][Full Text] [Related]
25. Follicular drug eruption induced by gefitinib (ZD 1839, iressa): clinical picture correlates with in vitro data of focal epidermal necrosis after epidermal growth factor inhibition in skin cultures.
Treudler R; Zouboulis CC
Dermatology; 2005; 211(4):375-6. PubMed ID: 16286753
[No Abstract] [Full Text] [Related]
26. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors.
Galimont-Collen AF; Vos LE; Lavrijsen AP; Ouwerkerk J; Gelderblom H
Eur J Cancer; 2007 Mar; 43(5):845-51. PubMed ID: 17289377
[TBL] [Abstract][Full Text] [Related]
27. Grover's disease induced by cetuximab.
Tscharner GG; Bühler S; Borner M; Hunziker T
Dermatology; 2006; 213(1):37-9. PubMed ID: 16778425
[TBL] [Abstract][Full Text] [Related]
28. Rosaceiform eruption induced by cetuximab.
Fernández-Torres R; Martínez Gomez W; Cuevas Santos J; Paradela S; Fonseca Capdevila E
Eur J Dermatol; 2010; 20(3):392-3. PubMed ID: 20172848
[No Abstract] [Full Text] [Related]
29. Scalp pustules in a patient receiving chemotherapy.
Chiu HY; Chiu HC
JAMA; 2013 Sep; 310(10):1068-9. PubMed ID: 24026603
[No Abstract] [Full Text] [Related]
30. A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption.
Scope A; Lieb JA; Dusza SW; Phelan DL; Myskowski PL; Saltz L; Halpern AC
J Am Acad Dermatol; 2009 Oct; 61(4):614-20. PubMed ID: 19646778
[TBL] [Abstract][Full Text] [Related]
31. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption.
Scope A; Agero AL; Dusza SW; Myskowski PL; Lieb JA; Saltz L; Kemeny NE; Halpern AC
J Clin Oncol; 2007 Dec; 25(34):5390-6. PubMed ID: 18048820
[TBL] [Abstract][Full Text] [Related]
32. Acneiform eruption induced by cetuximab.
Cotena C; Gisondi P; Colato C; Girolomoni G
Acta Dermatovenerol Croat; 2007; 15(4):246-8. PubMed ID: 18093454
[TBL] [Abstract][Full Text] [Related]
33. Severe acneiform rash.
Yamamoto DS; Viale PH; Zhao G
Clin J Oncol Nurs; 2004 Dec; 8(6):654-6. PubMed ID: 15637959
[No Abstract] [Full Text] [Related]
34. The management of EGFR inhibitor adverse events: a case series and treatment paradigm.
Wnorowski AM; de Souza A; Chachoua A; Cohen DE
Int J Dermatol; 2012 Feb; 51(2):223-32. PubMed ID: 22250636
[TBL] [Abstract][Full Text] [Related]
35. Erlotinib-induced dermatologic side-effects.
Bovenschen HJ; Alkemade JA
Int J Dermatol; 2009 Mar; 48(3):326-8. PubMed ID: 19261029
[No Abstract] [Full Text] [Related]
36. Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients.
de Noronha e Menezes NM; Lima R; Moreira A; Varela P; Barroso A; Baptista A; Parente B
Eur J Dermatol; 2009; 19(3):248-51. PubMed ID: 19258241
[TBL] [Abstract][Full Text] [Related]
37. Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitors.
Brodell LA; Hepper D; Lind A; Gru AA; Anadkat MJ
J Cutan Pathol; 2013 Oct; 40(10):865-70. PubMed ID: 23941617
[TBL] [Abstract][Full Text] [Related]
38. Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists.
Hassel JC; Kripp M; Al-Batran S; Hofheinz RD
Onkologie; 2010; 33(3):94-8. PubMed ID: 20215799
[TBL] [Abstract][Full Text] [Related]
39. Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
Santoro F; Cozzani E; Parodi A
J Dermatolog Treat; 2006; 17(3):160-1. PubMed ID: 16854757
[TBL] [Abstract][Full Text] [Related]
40. Papulopustular acneiform eruptions resulting from trastuzumab, a HER2 inhibitor.
Sheu J; Hawryluk EB; Litsas G; Thakuria M; LeBoeuf NR
Clin Breast Cancer; 2015 Feb; 15(1):e77-81. PubMed ID: 25445421
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
